ENHERTU® (fam-trastuzumab deruxtecan-nxki) HCP

Enhertu® (fam-trastuzumab deruxtecan-nxki) hcp email format

Verified email-pattern data for Enhertu® (Fam-Trastuzumab Deruxtecan-Nxki) Hcp is currently limited. You can still use the company insights and contact sections below.
Please see full Important Safety Information (ISI) below & at https://www.enhertuhcp.com/en/#isi Select ISI Selected Information Regarding Warnings and Precautions ENHERTU is associated with a number of serious, potentially fatal, Warnings and Precautions, including Interstitial Lung Disease/Pneumonitis, Neutropenia, Left Ventricular Dysfunction, Embryo-Fetal Toxicity. Please see Important Safety Information. For complete list of ENHERTU Indications, visit www.enhertuhcp.com. For US HCPs only. ENHERTU® is a Daiichi Sankyo & AstraZeneca brand & is not associated with any individual users. To report SUSPECTED ADVERSE REACTIONS, contact Daiichi Sankyo, Inc. at 1-877-437-7763 or FDA at 1-800-FDA-1088 or fda.gov/medwatch.
Looking for a particular ENHERTU® (fam-trastuzumab deruxtecan-nxki) HCP employee's phone or email?

Enhertu® (Fam-Trastuzumab Deruxtecan-Nxki) Hcp Questions

Top ENHERTU® (fam-trastuzumab deruxtecan-nxki) HCP Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant